Recovery Protocol

Overview

The recovery protocol centers on the synergistic combination of BPC-157 and TB-500, two peptides that have been widely studied for their roles in tissue repair and regeneration. While each compound has independent mechanisms of action, their combined use has become one of the most commonly referenced peptide stacks in the research community.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from human gastric juice that has demonstrated tissue-protective and regenerative properties across multiple tissue types in preclinical research. TB-500 (Thymosin Beta-4 fragment) is a synthetic version of a naturally occurring 43-amino-acid peptide involved in cell migration, blood vessel formation, and the regulation of actin — a critical protein in cellular repair processes.

The rationale for combining these two peptides is that they appear to support healing through complementary pathways: BPC-157 promotes angiogenesis and modulates nitric oxide signaling at the injury site, while TB-500 supports cellular migration and reduces inflammation through actin sequestration. Together, they may address both the structural and inflammatory components of tissue damage.

Compounds Involved

Protocol Structure

This protocol is typically divided into two distinct phases: a loading phase designed to establish tissue saturation, followed by a maintenance phase for continued support during the later stages of recovery.

Phase 1: Loading Phase (Weeks 1–4)

The loading phase uses higher frequency and dosing to initiate the repair cascade during the acute or subacute stage of injury.

BPC-157:

• Dose: 250–500 mcg per day
• Frequency: Once or twice daily (split dosing may be used for twice-daily administration, e.g., 250 mcg morning and 250 mcg evening)
• Injection site: Subcutaneous, ideally as close to the injury site as practical. For systemic issues, abdominal injection is standard
• Timing: No specific fasting requirement; can be administered at any time

TB-500:

• Dose: 2–5 mg per injection
• Frequency: Twice per week (e.g., Monday and Thursday)
• Injection site: Subcutaneous, abdomen or near the injury area
• Timing: No strict fasting requirement

Phase 2: Maintenance Phase (Weeks 5–8)

Once the initial loading is complete, the maintenance phase reduces dosing frequency while sustaining the reparative environment.

BPC-157:

• Dose: 200–250 mcg per day
• Frequency: Once daily
• Continue for: 4–8 additional weeks depending on recovery progress

TB-500:

• Dose: 2 mg per injection
• Frequency: Once per week
• Continue for: 4–8 additional weeks

Phase Summary Table

Total Protocol Duration

A typical recovery protocol runs 8–12 weeks in total. Some researchers extend the maintenance phase for chronic or severe injuries, while shorter protocols of 4–6 weeks may be used for minor soft tissue concerns.

Injection Site Strategy

A common approach is to inject as close to the affected area as possible:

• Tendon or ligament injuries: SubQ injection near the affected joint
• Muscle injuries: SubQ injection over the affected muscle belly
• General recovery or systemic support: Standard abdominal SubQ injection
• Gut-related issues: BPC-157 may be administered orally (see Gut Healing Protocol)

For site rotation guidance, see Subcutaneous Injection.

Reconstitution and Preparation

Both peptides arrive in lyophilized form and require reconstitution with bacteriostatic water before use.

Typical reconstitution example for BPC-157 (5 mg vial):

• Add 2 mL bacteriostatic water = 2,500 mcg/mL
• For a 250 mcg dose: draw 0.1 mL (10 units on an insulin syringe)

Typical reconstitution example for TB-500 (5 mg vial):

• Add 1 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL)
• For a 2.5 mg dose: draw 0.5 mL (50 units)

Important Considerations

• Synergy, not redundancy: BPC-157 and TB-500 operate through distinct mechanisms. Using both does not create duplication but rather addresses different aspects of the healing process.
• Injury severity matters: More severe or chronic injuries may warrant the higher end of the dosing range during loading. Minor strains may respond well to lower doses.
• Patience with timelines: Tissue repair is a biological process with inherent timelines. Most users in community reports note improvements beginning around weeks 2–3, with continued progress through the maintenance phase.
• Physical therapy complement: Peptides do not replace rehabilitation. Combining this protocol with appropriate physical therapy, mobility work, and progressive loading typically yields the best outcomes.
• Cycling: For extended use beyond 12 weeks, consider implementing an off period. See Peptide Cycling for receptor sensitivity management.
• Storage: Reconstituted BPC-157 and TB-500 should be refrigerated at 2–8 degrees Celsius and used within 3–4 weeks. See Peptide Storage for detailed guidelines.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.